Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047346 · ClinicalTrials.gov registry record · Phase 1
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
A Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00047346: Completed Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by National Cancer Institute (NCI).
NCT00047346 is a Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 27-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047346, a Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG erlotinib hydrochloride
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-08 |
| Phase | Phase 1 |
What the finished NCT00047346 record still lists
NCT00047346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 27-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (11% lower).
The record links to 4 conditions, with Advanced Adult Primary Liver Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00047346 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00047346 about?
NCT00047346 is a clinical study titled "Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction". Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
What is the current status of trial NCT00047346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-08.
What conditions does trial NCT00047346 study?
This clinical trial studies the following conditions: Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Adult Primary Hepatocellular Carcinoma.
What interventions are being tested in trial NCT00047346?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00047346?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047346 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Primary Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
COMPLETED · Phase 1
-
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
COMPLETED · Phase 1
-
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia